Tang Capital Management
Latest statistics and disclosures from Tang Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRTX, IMGN, TARS, KALV, LIAN, and represent 26.37% of Tang Capital Management's stock portfolio.
- Added to shares of these 10 stocks: MRTX (+$81M), LIAN (+$34M), PTCT (+$25M), IMGN (+$21M), GRCL (+$20M), RVMD (+$20M), CRSP (+$14M), THRX (+$13M), GSK (+$11M), BEAM (+$9.5M).
- Started 30 new stock positions in NUVB, TRVI, CRSP, THRX, KNTE, PTCT, MCRB, SYRS, AMLX, IOVA.
- Reduced shares in these 10 stocks: Eqrx (-$22M), THRD (-$12M), NVCR (-$7.9M), NTLA (-$6.0M), BCRX (-$6.0M), ITCI (-$5.7M), AVRO (-$5.4M), C, NKTX, ASLN.
- Sold out of its positions in IVVD, ASLN, AVRO, BNOX, C, CHRS, Eqrx, GLPG, Inspirato Incorporated, DERM. THRD, RNAZ, NVCR.
- Tang Capital Management was a net buyer of stock by $243M.
- Tang Capital Management has $1.1B in assets under management (AUM), dropping by 52.71%.
- Central Index Key (CIK): 0001232621
Tip: Access up to 7 years of quarterly data
Positions held by Tang Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Tang Capital Management
Tang Capital Management holds 123 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Mirati Therapeutics (MRTX) | 8.5 | $92M | +765% | 1.6M | 58.75 |
|
ImmunoGen (IMGN) | 6.0 | $65M | +46% | 2.2M | 29.65 |
|
Tarsus Pharmaceuticals (TARS) | 4.1 | $45M | +2% | 2.2M | 20.25 |
|
Kalvista Pharmaceuticals (KALV) | 3.9 | $42M | 3.4M | 12.25 |
|
|
Lianbio Sponsored Ads (LIAN) | 3.9 | $42M | +420% | 9.4M | 4.47 |
|
Anaptysbio Inc Common (ANAB) | 3.9 | $42M | 2.0M | 21.42 |
|
|
Mirum Pharmaceuticals (MIRM) | 3.1 | $34M | 1.1M | 29.52 |
|
|
Evolus (EOLS) | 3.0 | $33M | 3.1M | 10.53 |
|
|
Altimmune Com New (ALT) | 2.9 | $31M | 2.8M | 11.25 |
|
|
Immunocore Hldgs Ads (IMCR) | 2.6 | $28M | 406k | 68.32 |
|
|
Axsome Therapeutics (AXSM) | 2.4 | $26M | 320k | 79.59 |
|
|
Ptc Therapeutics I (PTCT) | 2.3 | $25M | NEW | 900k | 27.56 |
|
Gracell Biotechnologies Sponsored Ads (GRCL) | 2.0 | $22M | +1277% | 2.2M | 10.04 |
|
Revolution Medicines (RVMD) | 1.8 | $20M | NEW | 680k | 28.68 |
|
Vaxcyte (PCVX) | 1.7 | $19M | 300k | 62.80 |
|
|
Eli Lilly & Co. (LLY) | 1.6 | $18M | 30k | 582.92 |
|
|
New York Community Ban (NYCB) | 1.5 | $16M | 1.6M | 10.23 |
|
|
Intra Cellular Therapies (ITCI) | 1.5 | $16M | -26% | 220k | 71.62 |
|
Beigene Sponsored Adr (BGNE) | 1.4 | $15M | 85k | 180.36 |
|
|
Avadel Pharmaceuticals Sponsored Adr (AVDL) | 1.4 | $15M | +7% | 1.1M | 14.12 |
|
Miragen Therapeutics (VRDN) | 1.4 | $15M | +3% | 693k | 21.78 |
|
Crispr Therapeutics Namen Akt (CRSP) | 1.2 | $14M | NEW | 215k | 62.60 |
|
Theseus Pharmaceuticals (THRX) | 1.2 | $13M | NEW | 3.3M | 4.05 |
|
Atea Pharmaceuticals (AVIR) | 1.1 | $12M | +13% | 4.1M | 3.05 |
|
Astrazeneca Sponsored Adr (AZN) | 1.1 | $11M | 170k | 67.35 |
|
|
Zymeworks Del (ZYME) | 1.1 | $11M | 1.1M | 10.39 |
|
|
GSK Sponsored Adr (GSK) | 1.0 | $11M | NEW | 300k | 37.06 |
|
Kiniksa Pharmaceuticals Com Cl A (KNSA) | 1.0 | $11M | 600k | 17.54 |
|
|
Cytomx Therapeutics (CTMX) | 0.9 | $10M | 6.6M | 1.55 |
|
|
Ionis Pharmaceuticals (IONS) | 0.9 | $10M | 200k | 50.59 |
|
|
Beam Therapeutics (BEAM) | 0.9 | $9.5M | NEW | 350k | 27.22 |
|
Cytokinetics Com New (CYTK) | 0.8 | $9.2M | NEW | 110k | 83.49 |
|
Ascendis Pharma A/s Sponsored Adr (ASND) | 0.8 | $8.8M | +600% | 70k | 125.95 |
|
Harmony Biosciences Hldgs In (HRMY) | 0.8 | $8.8M | 271k | 32.30 |
|
|
Cymabay Therapeutics (CBAY) | 0.8 | $8.3M | +75% | 350k | 23.62 |
|
Iovance Biotherapeutics (IOVA) | 0.8 | $8.1M | NEW | 1.0M | 8.13 |
|
Cullinan Oncology (CGEM) | 0.7 | $7.9M | +24% | 771k | 10.19 |
|
Moderna (MRNA) | 0.7 | $7.6M | 77k | 99.45 |
|
|
Rocket Pharmaceuticals (RCKT) | 0.7 | $7.5M | +66% | 250k | 29.97 |
|
Graphite Bio (GRPH) | 0.6 | $6.5M | +23% | 2.5M | 2.62 |
|
Bioatla (BCAB) | 0.6 | $6.2M | -33% | 2.5M | 2.46 |
|
Kinnate Biopharma (KNTE) | 0.6 | $6.2M | NEW | 2.6M | 2.37 |
|
Adma Biologics (ADMA) | 0.6 | $6.1M | 1.4M | 4.52 |
|
|
Intellia Therapeutics (NTLA) | 0.6 | $6.1M | -49% | 200k | 30.49 |
|
CVB Financial (CVBF) | 0.6 | $6.1M | +50% | 300k | 20.19 |
|
Verastem Com New (VSTM) | 0.6 | $6.0M | -16% | 742k | 8.14 |
|
Biohaven (BHVN) | 0.6 | $6.0M | 140k | 42.80 |
|
|
Equity Comwlth Com Sh Ben Int (EQC) | 0.5 | $5.8M | 300k | 19.20 |
|
|
Esperion Therapeutics (ESPR) | 0.5 | $5.5M | 1.9M | 2.99 |
|
|
Reneo Pharmaceuticals (RPHM) | 0.5 | $5.3M | NEW | 3.3M | 1.60 |
|
Nuvation Bio Com Cl A (NUVB) | 0.5 | $5.3M | NEW | 3.5M | 1.51 |
|
Dianthus Therapeutics (DNTH) | 0.5 | $5.2M | -14% | 504k | 10.40 |
|
Bio Rad Labs Cl A (BIO) | 0.5 | $5.2M | -33% | 16k | 322.89 |
|
Insmed Com Par $.01 (INSM) | 0.5 | $5.2M | 166k | 30.99 |
|
|
Black Diamond Therapeutics (BDTX) | 0.5 | $5.1M | +350% | 1.8M | 2.81 |
|
Aurinia Pharmaceuticals (AUPH) | 0.5 | $4.9M | -26% | 550k | 8.99 |
|
Ventyx Biosciences (VTYX) | 0.5 | $4.9M | NEW | 2.0M | 2.47 |
|
Veritex Hldgs (VBTX) | 0.5 | $4.9M | 210k | 23.27 |
|
|
BioCryst Pharmaceuticals (BCRX) | 0.4 | $4.8M | -55% | 800k | 5.99 |
|
Rain Therapeutics (RAIN) | 0.4 | $4.6M | +2% | 3.9M | 1.20 |
|
Blueprint Medicines (BPMC) | 0.4 | $4.6M | NEW | 50k | 92.24 |
|
Us Bancorp Del Com New (USB) | 0.4 | $4.3M | 100k | 43.28 |
|
|
Dynavax Technologies Corp Com New (DVAX) | 0.4 | $4.2M | 300k | 13.98 |
|
|
Bolt Biotherapeutics (BOLT) | 0.4 | $4.1M | +2% | 3.7M | 1.12 |
|
Uniqure Nv SHS (QURE) | 0.4 | $4.1M | -35% | 600k | 6.77 |
|
Design Therapeutics (DSGN) | 0.4 | $3.9M | +9% | 1.5M | 2.65 |
|
Cargo Therapeutics | 0.3 | $3.7M | NEW | 161k | 23.15 |
|
Springworks Therapeutics (SWTX) | 0.3 | $3.7M | NEW | 100k | 36.50 |
|
Nkarta (NKTX) | 0.3 | $3.6M | -50% | 550k | 6.60 |
|
Bank of Hawaii Corporation (BOH) | 0.3 | $3.6M | +66% | 50k | 72.46 |
|
ACADIA Pharmaceuticals (ACAD) | 0.3 | $3.6M | +14% | 114k | 31.31 |
|
Century Therapeutics (IPSC) | 0.3 | $3.5M | NEW | 1.1M | 3.32 |
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.3 | $3.5M | -15% | 4.4M | 0.79 |
|
Cortexyme (QNCX) | 0.3 | $3.4M | -7% | 3.2M | 1.05 |
|
Arvinas Ord (ARVN) | 0.3 | $3.3M | 80k | 41.16 |
|
|
Karuna Therapeutics Ord (KRTX) | 0.3 | $3.2M | 10k | 316.51 |
|
|
Heron Therapeutics (HRTX) | 0.3 | $3.1M | 1.9M | 1.70 |
|
|
Inflarx Nv (IFRX) | 0.3 | $3.1M | -33% | 1.9M | 1.63 |
|
Amylyx Pharmaceuticals (AMLX) | 0.3 | $2.9M | NEW | 200k | 14.72 |
|
Enanta Pharmaceuticals (ENTA) | 0.3 | $2.8M | NEW | 300k | 9.41 |
|
Athira Pharma (ATHA) | 0.3 | $2.8M | +226% | 1.2M | 2.43 |
|
Amarin Corp Spons Adr New (AMRN) | 0.2 | $2.7M | -47% | 3.1M | 0.87 |
|
Fate Therapeutics (FATE) | 0.2 | $2.6M | 700k | 3.74 |
|
|
Seres Therapeutics (MCRB) | 0.2 | $2.5M | NEW | 1.8M | 1.40 |
|
Passage Bio (PASG) | 0.2 | $2.4M | +500% | 2.4M | 1.01 |
|
Enzo Biochem (ENZ) | 0.2 | $2.4M | -22% | 1.7M | 1.39 |
|
Bluebird Bio (BLUE) | 0.2 | $2.3M | -60% | 1.7M | 1.38 |
|
Silverback Therapeutics (SPRY) | 0.2 | $2.2M | 410k | 5.48 |
|
|
Editas Medicine (EDIT) | 0.2 | $2.0M | 200k | 10.13 |
|
|
Servisfirst Bancshares (SFBS) | 0.2 | $2.0M | 30k | 66.63 |
|
|
Pds Biotechnology Ord (PDSB) | 0.2 | $2.0M | 400k | 4.97 |
|
|
Tango Therapeutics (TNGX) | 0.2 | $2.0M | 200k | 9.90 |
|
|
Elevation Oncology (ELEV) | 0.2 | $2.0M | -8% | 3.7M | 0.54 |
|
Mei Pharma (MEIP) | 0.2 | $1.9M | 326k | 5.80 |
|
|
Genfit S A Ads (GNFT) | 0.2 | $1.8M | -53% | 479k | 3.85 |
|
Aclaris Therapeutics (ACRS) | 0.2 | $1.8M | NEW | 1.8M | 1.05 |
|
Tg Therapeutics (TGTX) | 0.2 | $1.7M | 100k | 17.08 |
|
|
Adicet Bio (ACET) | 0.2 | $1.7M | -28% | 876k | 1.89 |
|
Aligos Therapeutics (ALGS) | 0.1 | $1.5M | -34% | 2.2M | 0.66 |
|
Lava Therapeutics Nv SHS (LVTX) | 0.1 | $1.3M | NEW | 841k | 1.58 |
|
Nektar Therapeutics (NKTR) | 0.1 | $1.3M | -40% | 2.3M | 0.56 |
|
Alexandria Real Estate Equities (ARE) | 0.1 | $1.3M | NEW | 10k | 126.77 |
|
Precision Biosciences Ord (DTIL) | 0.1 | $1.2M | NEW | 3.4M | 0.36 |
|
908 Devices (MASS) | 0.1 | $1.1M | 100k | 11.22 |
|
|
Vanda Pharmaceuticals (VNDA) | 0.1 | $1.0M | NEW | 248k | 4.22 |
|
Acumen Pharmaceuticals (ABOS) | 0.1 | $948k | NEW | 247k | 3.84 |
|
Tusimple Hldgs Cl A (TSP) | 0.1 | $878k | NEW | 1.0M | 0.88 |
|
Gossamer Bio (GOSS) | 0.1 | $765k | 839k | 0.91 |
|
|
Atyr Pharma Com New (LIFE) | 0.1 | $664k | 471k | 1.41 |
|
|
Syros Pharmaceuticals Com New (SYRS) | 0.1 | $662k | NEW | 85k | 7.79 |
|
Eagle Pharmaceuticals (EGRX) | 0.1 | $622k | 119k | 5.23 |
|
|
Neuronetics (STIM) | 0.1 | $580k | 200k | 2.90 |
|
|
Stellar Bancorp Ord (STEL) | 0.1 | $557k | 20k | 27.84 |
|
|
Nextcure (NXTC) | 0.0 | $533k | +16% | 468k | 1.14 |
|
Molecular Partners Ads (MOLN) | 0.0 | $418k | 100k | 4.18 |
|
|
Trevi Therapeutics (TRVI) | 0.0 | $402k | NEW | 300k | 1.34 |
|
Xeris Pharmaceuticals (XERS) | 0.0 | $353k | 150k | 2.35 |
|
|
Erasca (ERAS) | 0.0 | $320k | NEW | 150k | 2.13 |
|
Kezar Life Sciences (KZR) | 0.0 | $291k | NEW | 307k | 0.95 |
|
Equillium (EQ) | 0.0 | $289k | 400k | 0.72 |
|
|
Selecta Biosciences (RNAC) | 0.0 | $276k | 400k | 0.69 |
|
|
Genedx Holdings Corp Com Cl A (WGS) | 0.0 | $175k | 64k | 2.75 |
|
|
Acelrx Pharmaceuticals Com New (ACRX) | 0.0 | $143k | 195k | 0.73 |
|
Past Filings by Tang Capital Management
SEC 13F filings are viewable for Tang Capital Management going back to 2011
- Tang Capital Management 2023 Q4 filed Feb. 14, 2024
- Tang Capital Management 2023 Q3 filed Nov. 14, 2023
- Tang Capital Management 2023 Q2 filed Aug. 14, 2023
- Tang Capital Management 2023 Q1 filed May 15, 2023
- Tang Capital Management 2022 Q4 filed Feb. 14, 2023
- Tang Capital Management 2022 Q3 filed Nov. 14, 2022
- Tang Capital Management 2022 Q2 filed Aug. 15, 2022
- Tang Capital Management 2022 Q1 filed May 16, 2022
- Tang Capital Management 2021 Q4 filed Feb. 14, 2022
- Tang Capital Management 2021 Q3 filed Nov. 15, 2021
- Tang Capital Management 2021 Q2 filed Aug. 16, 2021
- Tang Capital Management 2021 Q1 filed May 17, 2021
- Tang Capital Management 2020 Q4 filed Feb. 16, 2021
- Tang Capital Management 2020 Q3 filed Nov. 16, 2020
- Tang Capital Management 2020 Q2 filed Aug. 14, 2020
- Tang Capital Management 2020 Q1 filed May 15, 2020